Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
my pleasure - nice of you to mention
As GM-cSF controls CCR5 among many downstream cytokines- where is the science in claiming - as CYDY’s was called out for doing on twitter today by thought leader Brad Lonkind- that the product outperforms the producer? Nonsense. Today i found and released on Twitter numerous sources claiming GM-CSF may be responsible for Lack of smell, taste , and brain fog in Longhaul COVID- positions HGEN perfectly.
“GM-CSF has emerged as a potential biological target in treating severe COVID-19 (Zhou et al., 2020); this may mitigate neuropsychiatric sequelae by limiting MdC neuroinvasion.“ https://scholar.google.com.hk/scholar?as_ylo=2020&q=anosmia+gm-csf&hl=en&as_sdt=0,33#d=gs_qabs&u=%23p%3DGoaq9TmKdCgJ… $HGEN will treat #longhaulers NeuroCOVID - #COVID19 - not Roche, Incy or CYDY - HGEN.
https://www.researchgate.net/figure/CCR5-upregulation-mediated-by-IL-6-and-GM-CSF-in-vitro-MSC-2-cells-A-and-IMC-B-were_fig1_343616799/amp HGEN target governs CYDY’s as well as other cytokines - triggering the oft fatal storm.
AZN- another potential HGEN lenzilumab competitor fails -
AstraZeneca Cancer Drug Fails to Help Patients With Covid-19
By Marthe Fourcade
November 12, 2020, 2:29 AM EST
AstraZeneca Plc said its blood-cancer medicine Calquence failed to help patients hospitalized with respiratory symptoms of Covid-19.
The group of patients taking the drug in addition to standard care didn’t show fewer deaths or respiratory failures, the U.K. drugmaker said in a statement. Details of the intermediate clinical trials will be presented in due course, the company said.
https://www.google.com/amp/s/www.bloomberg.com/amp/news/articles/2020-11-12/astrazeneca-cancer-drug-fails-to-help-patients-with-covid-19
No ICU Beds left in TULSA - LLY early COVID Target - no CRADA - $HGEN - Late Target and CRADA - EUA soon
“There are no treatments for most viral causes of pneumonia. However, if the flu virus is thought to be the cause, antiviral drugs might be prescribed, such as oseltamivir (Tamiflu®), zanamivir (Relenza®), or peramivir (Rapivab®), to decrease the length and severity of the illness.- Cleveland Clinic
Tamiflu peak sales prior to generics-$3B
$HGEN Lenzilumab will be a Blockbuster.
No LLY CRADA BUT EUA - HGEN- CRADA And EUA.
Um PFE positive in 90% of only 94 pts per Financial Times -
HGEN “Reuters- CRADA after DSMB signaling of 37% improvement in Humanigen Hospitalized P3 patients- HGEN has partnered with the U.S. government to help advance development of its drug candidate as a potential COVID-19 treatment following positive response in hospitalized patients in a late-stage study, the company said on Friday.
Patients receiving the drug, lenzilumab, saw 37% more recovery as compared to current standard of care in the study reut.rs/2U0IPRi, which aims to determine whether the drug can prevent and treat an immune hyper-response called "cytokine storm".
The tie-up with the defense department is part of the U.S. government's Operation Warp Speed, which has struck deals with several other drugmakers to help speed up the development of a possible COVID-19 treatment”
https://www.google.com/amp/s/mobile.reuters.com/article/amp/idUSKBN27M1JX
Lenz will be Biden’s 1st COVID Moonshot! Great Point on Fauci.
RGEN CEO plays Golf with POTUS but only little $HGEN follows in $GILD’s footsteps with next CRADA- figure that on your scorecard.
HGEN funny -this interim top line P3 readout was pre announced weeks ago for Q4 - it was always anticipated - not a word till extremely positive. Go be fooled - I ain’t be I assure yo
Humanigen Inc (NASDAQ:HGEN) announced Wednesday that an abstract describing the ongoing ZUMA-19 lymphoma study of its drug lenzilumab has been accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition to be held virtually December 5-8.”
1 DC Patient -Go Long on Marc Short - look at news-anonymous sources say symptomatic then radio silence x 1 week.
"On Saturday, Short (VP Chief of Staff) was said to have been experiencing symptoms, according to two administration officials who spoke on the condition of anonymity to discuss a private matter."?
https://www.washingtonpost.com/politics/pences-chief-of-staff-marc-short-tests-positive-for-the-coronavirus/2020/10/24/c89c90bc-166d-11eb-bc10-40b25382f1be_story.html
Humanigen Announces First Patient Dosed at MedStar Washington Hospital Center in Phase 3 Clinical Study of Lenzilumab in COVID-19
Published: Oct 30, 2020
https://www.biospace.com/article/releases/humanigen-announces-first-patient-dosed-at-medstar-washington-hospital-center-in-phase-3-clinical-study-of-lenzilumab-in-covid-19
Samet/Medstar - Trump - $HGEN (has only therapeutic which can save lives by Tuesday). Bullish
Washington DC Hospital signs up to study fast acting potential $HGEN COVID therapeutic just ahead of election -hmm...
HGEN Announces First Patient Dosed at MedStar Washington Hospital Center in Phase 3 Clinical Study of Lenzilumab in COVID-19 | Business Wire P3 ready by Thanksgiving / Mayo Clinic patients discharged in 5 days. See link below??
“Nearly 90% of hospitalized COVID-19 patients progress to severe disease including the cytokine storm for some patients,” said Vincent C. Marconi, MD, professor of medicine and global health in Emory University School of Medicine and Emory’s Rollins School of Public Health. “There is a critical need for a novel COVID-19 therapeutic with potential to reduce patients’ time to recovery, and this study aims to streamline the pathway to finding these urgently needed treatments.”
“We are encouraged by lenzilumab’s efficacy and safety data demonstrated in hospitalized COVID-19 patients to date and believe we have a game-changing treatment with frontline potential,” said Cameron Durrant, MD, MBA, chief executive officer of Humanigen. “We are eager to put lenzilumab through further rigorous testing in this NIH ACTIV-5 study as we continue to advance our lead candidate in the next phases of development.”
https://www.streetinsider.com/dr/news.php?id=17528779&gfv=1
1st case Report on Election Day AM?
A Monday without M&A - many expecting positive Nov. data and all that comes with it- I am.
Scott Gottlieb claims Antibody drugs are coming out soon. On CNBC this AM around 6:45.
As $GILD Remdesivir gains FDA Approval - it’s Combined NIAID BET trial with HGEN Lenzilumab begins recruiting - with the current COVID wave - it should fill quickly.
Mint coming - be patient..
“ $NIO, Peloton Among Analyst's Top Short Squeeze Candidates” 10/20/20
https://www.google.com/amp/s/finance.yahoo.com/amphtml/news/nio-peloton-among-analysts-top-164505934.html
Cantor Fitzgerald 10/20/20 :
“Expecting positive Phase 3 data for COVID-19 opportunity. Lenzilumab could be the
first antibody approved for cytokine storm associated with COVD-19, and HGEN could
make up to $1B in sales in 2021”
Jim Birchenough WFC was the dean of HALO analysts and always got it right - now on HGEN calls he’s the first and most inquisitive analyst —I expect Overweight/$35 initiation.
If O’Day waits for NIAID BET data to Buy $HGEN, you can bet he’s waited a Day too late.
He has Lenzilumab-Yescarta open label data that NVS BMY PFE and REGN doesn’t have - should press his advantage before Fauci releases BET data to all.
https://www.google.com/amp/s/www.fool.com/amp/investing/2020/10/16/who-remdesivir-does-not-substantially-affect-covid/
HGEN “Phase III may not be necessary for approval in ZUMA-19; precedent is CAR-Ts to date have been approved on Phase II data in
UK
US, EU, Australia
Australia”
So $GILD May start using Lenzilumab to add value and safety to Yescarta sooner after the acquisition of HGEN.
HGEN - $GILD has a problem in severe COVID - “ WHO Director General Tedros Adhanom Ghebreyesus defended the so-called Solidarity Trial, which was launched to study the effectiveness of remdesivir and three other drugs in treating COVID-19, as the largest trial in the world. It included more than 11,000 coronavirus patients across 30 countries, with more than 2,700 participants given remdesivir.” No Benefit.
https://www.google.com/amp/s/www.usnews.com/news/health-news/articles/2020-10-16/who-addresses-gileads-pushback-on-remdesivir-trial%3fcontext=amp
AND they have access to UNblinded HGEN - Lenzilumab-Yescarta data - Cytokine storm In CAR-T is Cytokine storm in COVID- O’Day can treat two storms with one deal.
https://clinicaltrials.gov/ct2/show/NCT04314843?term=Lenzilumab&draw=2&rank=2
Jay, I’m So sorry for your loss. I imagine your conclusions about how Lenzilumab would have helped her will redouble your already impressive efforts to investigate and educate on its use.
Deepest Condolences,
Fez
HGEN GILD -WHO -“For the moment, the corticosteroid dexamethasone is still the only therapeutic shown to be effective against COVID-19, for patients with severe disease," Tedros said at a press conference.”
Remdesivir fail in world’s largest COVID study in severe disease means GILD is MORE likely to buy the company it has already exclusively partnered in CAR-T Cytokine Storm -HGEN.
https://www.google.com/amp/s/www.usnews.com/news/health-news/articles/2020-10-16/who-addresses-gileads-pushback-on-remdesivir-trial%3fcontext=amp
Thanks Jay- Good Idea- All should read this piece on HGEN GILD
Yes, Don’t you think we should buy islands Right next to “Knuckle Island” ?
Humanigen has publicized a poster on Lenzilumab - making neurotoxicity from CAR-T less likely as well as making CAR-T more effective - https://www.mdedge.com/hematology-oncology/article/195018/transplantation/anti-gm-csf-antibody-reduced-car-t-cell-toxicity -All tge writing is on the wall for a GILD buyout - though we’ll probably do better without it in the end.
GILD and Open Label CAR-T Lenzilumab Data- Key to M&A -
Remdesivir Fail in huge WHO trial will focus GILD attention on its partner in “Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma (ZUMA-19)“ more sharply - this is Open Label Data - certainly the better it is the more impetus GILD has to buy its partner and expand into Treatment of ARDS in Covid.
$HGEN “ Stop the Storm” New Website https://www.stopstorm.com
Fauci on HGEN : “ Study participants assigned to receive lenzilumab (HGEN) will be given a 600 mg intravenous infusion every eight hours for a total of three doses.
“The goal here is to identify as quickly as possible the experimental therapeutics that demonstrate the most clinical promise as COVID-19 treatments and move them into larger-scale testing,” NIAID director Anthony Fauci, MD, said in a statement. “This study design is both an efficient way of finding those promising treatments and eliminating those that are not.”
Genetic Engineering and Biotech News “ “Lenzilumab is among 19 “front runners” among the more than 300 drug and vaccine candidates tracked on GEN’s COVID-19 Drug & Vaccine Candidate Tracker.”